Mersana Therapeutics (NASDAQ:MRSN) Shares Up 3.7%
Mersana Therapeutics (NASDAQ:MRSN) Shares Up 3.7%
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s share price shot up 3.7% on Friday . The stock traded as high as $6.66 and last traded at $6.66. 2,607 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,150,149 shares. The stock had previously closed at $6.42.
默薩納治療公司(納斯達克代碼:MRSN-GET Rating)股價週五飆升3.7%,盤中一度漲至6.66美元,最新報6.66美元。午盤成交量為2,607股,較1,150,149股的平均成交量下跌100%。此前該股收盤價為6.42美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Several brokerages recently weighed in on MRSN. Robert W. Baird boosted their price objective on shares of Mersana Therapeutics from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 9th. Wedbush reaffirmed an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. Finally, SVB Leerink upped their price target on shares of Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
幾家券商最近加入了對MRSN的看法。羅伯特·W·貝爾德在8月9日星期二的一份研究報告中將Mersana治療公司的股票目標價從18.00美元上調至20.00美元,並給予該股“跑贏大盤”的評級。韋德布什在8月9日星期二的一份研究報告中重申了對Mersana治療公司股票的“跑贏大盤”評級。最後,SVB Leerink在8月9日星期二的一份研究報告中將Mersana Treeutics的股票目標價從13.00美元上調至14.00美元,並給予該公司“跑贏大盤”的評級。
Mersana Therapeutics Trading Up 5.9 %
Mersana治療公司股價上漲5.9%
The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.18. The stock's 50-day simple moving average is $6.85 and its 200 day simple moving average is $5.03.
該公司的流動比率為3.32,速動比率為3.32,債務權益比率為0.18。該股的50日簡單移動均線切入位為6.85美元,200日簡單移動均線切入位為5.03美元。
Hedge Funds Weigh In On Mersana Therapeutics
對衝基金入股Mersana Treeutics
A number of institutional investors and hedge funds have recently made changes to their positions in MRSN. Victory Capital Management Inc. bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $36,000. Quantbot Technologies LP bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $37,000. Washington University bought a new position in shares of Mersana Therapeutics during the 2nd quarter worth about $43,000. Virtu Financial LLC bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $53,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of Mersana Therapeutics during the 4th quarter worth about $57,000. Institutional investors own 95.12% of the company's stock.
一些機構投資者和對衝基金最近改變了他們在MRSN的頭寸。勝利資本管理公司在第一季度購買了價值約3.6萬美元的Mersana治療公司的新股票頭寸。Quantbot Technologies LP在第一季度購買了Mersana Treateutics的新頭寸,價值約3.7萬美元。華盛頓大學在第二季度購買了Mersana Treeutics的新頭寸,價值約43,000美元。Virtu Financial LLC在第一季度購買了Mersana Treeutics的新頭寸,價值約53,000美元。最後,Point72 Hong Kong Ltd在第四季度購買了Mersana Treeutics的新股票頭寸,價值約57,000美元。機構投資者持有該公司95.12%的股票。
About Mersana Therapeutics
關於Mersana Treeutics
(Get Rating)
(獲取評級)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Mersana治療公司是一家臨牀階段生物製藥公司,為未得到滿足需求的癌症患者開發抗體藥物結合物(ADC)。它開發了XMT-1592,一種針對NaPi2b表達腫瘤細胞的Dolasynten ADC,正在進行治療卵巢癌和NSCLC腺癌的I期臨牀試驗。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Let Paychex Stock Work Hard For You
- Thor Industries Hammers Out A Bottom
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免費獲取StockNews.com關於Mersana治療公司(MRSN)的研究報告
- 這是買入美光科技的難忘時刻
- 利潤下降對CarMax價值主張的挑戰
- 讓Paychex股票為您努力工作
- 雷神工業走出谷底
- Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何?
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Mersana治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Mersana Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。